Drugs / SAL0123
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07384104 | Oct 2025 → Feb 2026 overdue | osteoporosis | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Enrolling by invitation | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAL0123 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07384104 ↗ |